...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter

| Print |
Monday, 30 March 2009 09:29 (UTC + 2)


BioSquare_logo

  

Lyon, France, March 30, 2009 / b3c newswire / - The 2009 edition of the BioSquare business conference was held March 9-11 in Lyon. For three days, the 343 companies in attendance, including 11 big pharma companies, held some 2,500 business meetings. The conference created real dynamics in a difficult economic context by offering biotech and pharma company managers a solid chance to develop business opportunities, create partnerships and get acquainted with new technologies in booming biotech industries.

 

BioSquare 2009 geared to the biotech market and companies 

“For Biotech companies, the financing of innovation is essential, which may be quite a challenge in the current economic climate. Finding the right partners will be an even more critical factor of success. In just three days, BioSquare 2009 served as a place for business exchanges leading to international partnerships,” said Bernadette Guagliata, BioSquare’s CEO.


In order to maintain any kind of leadership in innovation during these difficult times, it is necessary to convince investors, to communicate knowledge and know-how effectively, to determine which sectors are most favourable in terms of growth, to set up strategic partnerships, and to know how to sign the right contract… By enabling biotech companies to get advice from renown experts in these key areas, through its thematic sessions, BioSquare has positioned itself as an event with high added value.


“With the ability to create synergies among the various technologies (high-tech, cleantech, biotech), to present young biotech companies, to cross-match information...BioSquare becomes a relevant business conference,” states Albin Jourda, CEO of Gallium Moore, a merger/acquisition consulting firm specialised in information technology, biotech and cleantech.

 

BioSquare 2009 sets up meetings, partnerships and businesses 

With more than 2,500 business meetings, the 343 biotech firms represented by more than 520 delegates turned BioSquare into an effective business and trade platform. 
On Tuesday alone, 11 pharmaceutical leaders including Johnson&Johnson, GSK, Bayer, Sanofi-Aventis and 20 Biotech companies including Ipsogen, Theregen, Biomay, Ascendis pharma– had the chance to expose their know-how and R&D programmes, with the evidence that their technologies need others to exist, grow and find the right market.
Gilles Rubinstenn, Managing Director of the Pierre-Gilles de Gennes Foundation, notes: “We got involved in preparing the thematic programme for BioSquare 2009 and we were especially satisfied with the return on this investment: The Foundation’s main objective is to bring the academic research sector together with innovative firms to set up projects with high added value. During these three days, 40 face-to-face meetings with biotech companies left us with 25 serious partnership prospects.”

 

BioSquare 2009 talks innovations and new applications for Biotech technologies  

For the 2009 edition’s scientific and strategic programme, BioSquare decided to give the floor to booming innovative industries like cleantech, stem cells and theranostics.
Regarding the workshop on theranostics, Marc Essodaigui, Vice President Marketing & Sales, Europe & Asia at Ipsogen, notes: “Theranostics as a concept has been around a long time but is coming into real applications now. A better understanding of diseases allows more targeted therapies; and these need increasingly high-performance diagnostic tools. The pharma industry and the biotechs are therefore working together, especially on cancer, where patient monitoring is essential and diagnostic tools have real benefit.” In the current economic situation, “The biotechs that have innovative diagnostic technologies have more of a trump card to play, especially in supporting pharma activity for clinical development,” he concludes.

 

BioSquare in 2010 

While fewer delegates attended the 2009 edition, activity remains strong. BioSquare 2009 shows that the biotechs are standing up to the crisis. “The continuous progress and discoveries in the field of biotechnology area - more than ever – opening new opportunities for Health, Agriculture, Energy-management and Pollution-control” As Bernadette Guagliata noted at the opening session, “This makes BioSquare even more important, because we can effectively and efficiently be a support, to optimise and stimulate the process of partnering and networking at an international level.”
BioSquare 2010 edition will be held in Switzerland in an entirely overhauled format for more effectiveness, more contacts and more deals.

 

 

Press contact

Frédéric Le Gall 
This e-mail address is being protected from spambots. You need JavaScript enabled to view it  
+33 (0)6 64 28 89 00

BioSquare Contact

Bernadette Guagliata
This e-mail address is being protected from spambots. You need JavaScript enabled to view it